🇺🇸United States
Idle Resources from Protocol Amendment Cycle Times
1 verified sources
Definition
Protocol amendments cause over 65-day median cycle times from issue identification to full implementation, idling sites, staff, and equipment. This leads to lost trial capacity and enrollment opportunities across biotech research workflows.[7]
Key Findings
- Financial Impact: $453,932 average per amendment implementation
- Frequency: Recurring - 3-5 amendments per trial
- Root Cause: Sequential re-approval processes across multiple IRBs and sites post-initiation
Why This Matters
This pain point represents a significant opportunity for B2B solutions targeting Biotechnology Research.
Affected Stakeholders
Clinical Trial Managers, Site Staff, Regulatory Affairs Specialists
Action Plan
Run AI-powered research on this problem. Each action generates a detailed report with sources.
Methodology & Sources
Data collected via OSINT from regulatory filings, industry audits, and verified case studies.
Related Business Risks
Protocol Approval Delays Driving Trial Start-Up Time Drag
$55,716 per day Phase III trial delay; ~$390,000 per delayed week per site
High IRB/Ethics Committee Fees and Site Activation Delays
$1,000-$5,000+ per site IRB fee; $30,000-$200,000 total per site activation
Excessive Protocol Amendments in Research Protocol Development
$250,000-$450,000 per amendment
High Development Costs and Funding Shortfalls
$Hundreds of millions per project in unrecouped development costs
Civil Money Penalties for ClinicalTrials.gov Non-Compliance in Biotech Trials
$10,000 per day per violation
Publish-or-Perish Conflicts with Patent Timing
$Reduced royalties over shortened patent life (estimable in millions for successful drugs)